🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementThrew up at work today - do I tell my boss why?

Threw up at work today - do I tell my boss why?

NurseAsh_DET Fri, Apr 10, 2026 at 1:24 AM 7 replies 614 viewsPage 1 of 2
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Apr 10, 2026 at 1:24 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What would genuinely help is knowing what distinguishes the nausea you can titrate through from the nausea that means stop.

I would rather have one careful answer than five confident ones.

50 20FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 47 others
Reply Quote Save Share Report
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Apr 10, 2026 at 1:59 AM#2

Taking the question as asked, rather than the general version of it. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

49 19marcus_mpls, DeniseRN_TPA, SandraNC_45 and 46 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Apr 10, 2026 at 2:34 AM#3
MikeFit_NJ said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

48 18AttorneyGrant, DebRD_ATL, KristenIndy and 45 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Apr 10, 2026 at 3:09 AM#4
NurseAsh_DET said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

This matches mine closely enough to be worth saying so. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Apr 10, 2026 at 9:09 AM
47 17BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 44 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Apr 10, 2026 at 6:26 AM#5

From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

46 16Dr.ObesityLA, NurseKim_ATL, paul_denver and 43 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register